MediciNov Sees Volume After Zacks Research Raises Price Target To $28

  • MediciNov Inc MNOV sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock price target to $28 from $26.5 earlier.
  • The research notes positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) published in Translational Psychiatry.
  • While ibudilast did not significantly affect negative mood, it reduced the odds of heavy drinking across time by 45%, attenuated alcohol cue-elicited activation in the ventral striatum compared to placebo.
  • It also reduced alcohol craving compared to placebo on non-drinking days.
  • There were no significant differences between groups on any baseline characteristic, and overall medication compliance was high.
  • Price Action: During the mid-day session, the stock was trading 7.38% lower at $3.89 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: BiotechNewsPenny StocksHealth CarePrice TargetAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!